MEI Pharma Inc (MEIP) News

Form 8-K - Current report

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

– Ongoing Phase 1b Study Evaluating ME-344 Plus Avastin® in Patients with Metastatic Colorectal Cancer: Combination Intended to Create Metabolic...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity – – Initial Results from...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]